Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: NOVARTIS
Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A one year multicenter, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of a single intravenous 5 mg dose zoledronic acid for the treatment of osteoporosis in men
The primary objectives are to demonstrate the superiority of treatment with zoledronic acid Calcium and Vitamin D relative to placebo Calcium and Vitamin D regarding the percent change of BMD at ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A Multicenter, Double-Blind,Randomized, Active Controlled Study to Compare the Effect of Long Term Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily in Drug Na?ve Patients with Type 2 Diabetes
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease patients requiring levodopa
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
Not available
Not available
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS PHARMA SAS
Update Il y a 4 ans
Etude ouverte, multicentrique, de 24 semaines, évaluant l'efficience clinique de la forme Exelon patch 10 cm2 chez des patients avec une maladie d'Alzheimer (MMSE 10-26)
Confirmer l'efficience clinique d'Exelon patch en déterminant en pratique courante le pourcentage de patients qui peuvent atteindre et maintenir pendant au moins 8 semaines la posologie maximale (Exel...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIABETES
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS PHARMA SAS
Update Il y a 4 ans
Study of quality of life in chronic Spontaneous Urticaria patients and treated by omalizumab (Xolair®) Etude de qualité de vie chez les patients souffrant d'urticaire chronique spontanée et traités par omalizumab (Xolair®)
Evaluate the proportion of patients achieving disease control (urticaria control test [UCT] score of greater than or equal to 12) at Week 12 in adult patients with CSU with inadequate response to H1 a...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney
To assess the treatment effect on progression-free survival (PFS) of patients who receive RAD001 plus bevacizumab versus patients who receive IFN plus bevacizumab based on an estimation of the chance ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
Extension to a multicentre, randomized, crossover, open labeldose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 mcg b.i.d.) and doses of open label of Sandostatin (100 mcg t.i.d.)in acromegalic patients
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A multicentre, randomized, double-blind, placebocontrolled, parallel-group phase II study on the efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genotype 1 patients who are previous peg-IFN alfa-2 plus ribavirin treatment-nonresponders
To evaluate whether the proportion of patients who achieve cEVR (by Limit of Quantitation, LOQ, i.e. HCV RNA < 25 IU/mL) after 12 weeks of triple therapy with DEB025 600 mg/day combined with peg-IFN...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next